Invictus MD Strategies (Invictus MD Strategies) EBITDA Margin % : -949.21% (As of Oct. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Invictus MD Strategies's EBITDA for the three months ended in Oct. 2019 was $-6.04 Mil. Invictus MD Strategies's Revenue for the three months ended in Oct. 2019 was $0.64 Mil. Therefore, Invictus MD Strategies's EBITDA margin for the quarter that ended in Oct. 2019 was -949.21%.

Invictus MD Strategies EBITDA Margin % Historical Data

The historical data trend for Invictus MD Strategies's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invictus MD Strategies EBITDA Margin % Chart

Invictus MD Strategies Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

EBITDA Margin %

0.58

-237.44

-794.06

-711.82

Invictus MD Strategies Quarterly Data
	Jan15	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19
EBITDA Margin %	Get a 7-Day Free Trial															-951.49	-391.72	-228.33	-284.80	-949.21

Competitive Comparison of Invictus MD Strategies's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Invictus MD Strategies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invictus MD Strategies's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invictus MD Strategies's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Invictus MD Strategies's EBITDA Margin % falls into.

Invictus MD Strategies EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Invictus MD Strategies's EBITDA Margin % for the fiscal year that ended in Jan. 2019 is calculated as

EBITDA Margin %	=	EBITDA (A: Jan. 2019 )	/	Revenue (A: Jan. 2019 )
	=	-25.12	/	3.529
	=	-711.82 %

Invictus MD Strategies's EBITDA Margin % for the quarter that ended in Oct. 2019 is calculated as

EBITDA Margin %	=	EBITDA (Q: Oct. 2019 )	/	Revenue (Q: Oct. 2019 )
	=	-6.037	/	0.636
	=	-949.21 %

Invictus MD Strategies (OTCPK:IVITF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Invictus MD Strategies EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Invictus MD Strategies's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Invictus MD Strategies (Invictus MD Strategies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1

Website

http://www.invictus-md.com

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.